- Evotec’s subsidiary Just – Evotec Biologics has been selected for a BARDA BioMaP program worth up to $10 million to optimise manufacturing of monoclonal antibody therapies targeting filoviruses.
- The program focuses on Ebola and Sudan virus therapies, supporting U.S. preparedness through scalable and cost-efficient manufacturing processes.
Evotec SE has announced that its Seattle-based CDMO subsidiary, Just – Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) BioMaP Consortium to support manufacturing optimisation for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus and Sudan virus.
The multi-year agreement, valued at up to $10 million if all options are exercised, is intended to support the development of medical countermeasures that can strengthen U.S. preparedness for public health emergencies. The programme includes a base period and two optional extensions. While treatments are available for Ebola virus disease, no approved therapies currently exist for Sudan virus infections.
Under the contract, Just – Evotec Biologics will apply its technology platforms to conduct molecular optimisation, cell line development, and manufacturing process development for two monoclonal antibodies. These antibodies were originally identified in survivors of the 2014 Ebola outbreak and are being developed into scalable and cost-efficient manufacturing processes.
The work will be carried out using the company’s platform technologies to enable high-yield production and support potential future deployment of therapeutics in emergency scenarios. The initiative aligns with BARDA’s efforts to expand manufacturing readiness and improve access to biologics in outbreak situations.
“In outbreak scenarios, speed, scalability and manufacturing robustness are critical. Our technology-driven approach is designed to deliver resilient, industry-leading high-yield production processes that can support rapid deployment in public health emergencies.”
Linda Zuckerman, EVP Global Head of Biotherapeutics at Just – Evotec Biologics
